Synergy CHC Corp Reports Growth in Earnings Per Share for its First Quarter 2025 Financial Results and its Ninth Consecutive Quarter of Profitability

Rhea-AI Summary

Synergy CHC Corp (NASDAQ: SNYR) reported its Q1 2025 financial results, marking its ninth consecutive quarter of profitability. The company achieved a 30% growth in earnings per share to $0.10 compared to $0.08 in Q1 2024. While revenue decreased 13% to $8.2 million from $9.4 million, gross margin improved to 75.4% from 72.0%. Net income increased 51% to $876.3 thousand, and EBITDA grew 7% to $1.98 million. Operating expenses decreased 15% to $4.2 million. The company is pursuing international expansion for its FOCUSfactor brand and Ready-To-Drink beverages into three new markets. Synergy has entered debt refinancing negotiations to extend maturity to 2029, established a subsidiary in Mexico, and signed a new long-term supplier agreement for FOCUSfactor products. The company reduced outstanding liabilities by $1.7 million during Q1 2025.

Positive

• 30% year-over-year growth in earnings per share ($0.10 vs $0.08)
• 51% increase in net income to $876.3K from $580.5K
• Improved gross margin to 75.4% from 72.0%
• EBITDA margin expansion to 24.1% from 19.7%
• 15% reduction in operating expenses to $4.2M
• $1.7M reduction in outstanding liabilities
• New long-term supplier agreement expected to deliver significant cost savings

Negative

• 13% decline in revenue to $8.2M from $9.4M
• Cash and cash equivalents decreased to $177.9K from $687.9K
• Negative operating cash flow of $822.8K
• High total liabilities of $31.3M requiring refinancing

Insights

Financial Analyst

Synergy delivered 51% net income growth despite 13% revenue decline, with expanding margins and upcoming debt refinancing providing cash flow flexibility.

Synergy's Q1 2025 results reveal a compelling profitability story despite revenue headwinds. The company achieved 30% EPS growth year-over-year (from $0.08 to $0.10) and 51% net income growth (from $580.5k to $876.3k), marking its ninth consecutive profitable quarter. However, revenue declined 13% to $8.2M, attributed to a non-recurring product sell-in from 2024.

What's particularly impressive is Synergy's margin expansion. Gross margin improved from 72.0% to 75.4% due to favorable product mix shifts, while EBITDA margin expanded significantly from 19.7% to 24.1%. The company effectively reduced operating expenses by 15% to $4.2M, driving an 8% increase in operating income to $1.9M.

The balance sheet shows mixed signals. Cash decreased from $687.9k to $177.9k during Q1, while inventory increased from $1.7M to $2.3M. However, the company reduced total liabilities by $1.7M to $31.3M, demonstrating commitment to strengthening its financial position. Cash used in operations slightly improved year-over-year.

The pending debt refinancing represents a significant catalyst, potentially extending maturity to 2029 and accelerating free cash flow generation. Meanwhile, strategic initiatives including international expansion into three new markets for FOCUSfactor, developing GLP-1 support products, and a new supplier agreement for FOCUSfactor (effective April 2025) position the company for future growth despite the revenue decline this quarter.

WESTBROOK, Maine, May 15, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a provider of consumer health care and lifestyle products, is announcing its financial results for the three months ended March 31, 2025.

“We are very pleased to report 30% growth in earnings per share year-over-year, marking our ninth consecutive quarter of profitability,” said Jack Ross, CEO of Synergy. “Additionally, we expanded our EBITDA margins significantly to 24.1% compared to 19.7% in the prior year period. This performance highlights the strength of our operating model and our ongoing discipline around cost management.”

“We continue to make meaningful progress toward our 2025 priorities, including preparing for international expansion into three new markets later this year for our FOCUSfactor brand and Ready-To-Drink beverages, and expanding our Flat Tummy product line in response to rising interest in GLP-1 support. We also successfully entered into term sheets to refinance our debt that we expect to close as expeditiously as possible, which is expected to accelerate free cash flow in the business in the near term and extend our debt maturity date into 2029. This will provide us the added flexibility to pursue our long-term strategic goals and accelerate our 2025 growth initiatives. With continued momentum and the expected refinancing, Synergy has a clear path forward. We remain confident in our ability to drive sustainable growth and shareholder value. We are truly excited about our ability to accelerate our growth initiatives in the coming quarters.”

First Quarter 2025 Financial Summary vs. Same Year-Ago Period

• Revenue of $8.2 million vs. $9.4 million.
• Gross margin of 75.4% vs. 72.0%.
• Income from operations of $1.9 million vs. $1.8 million.
• Net income of $876.3 thousand vs. $580.5 thousand.
• Earnings per share of $0.10 vs. $0.08.
• EBITDA, a non-GAAP financial measure, was $1.98 million vs. $1.85 million.

Recent Business Highlights

• Synergy entered and continued debt refinancing negotiations during and after the first quarter, aiming to extend the maturity to 2029.
• Synergy has established a wholly owned subsidiary in Mexico and is actively working to onboard several key suppliers and retailers in the region.
• Synergy signed a new long-term supplier agreement for FOCUSfactor products, effective April 2025, which is expected to deliver significant cost savings.
• During the first quarter, the Company reduced outstanding liabilities by $1.7 million.

First Quarter 2025 Financial Results

Revenue in the first quarter of 2025 was $8.2 million, down 13% compared to $9.4 million in the first quarter of 2024. The decrease was driven by a new product sell-in to one customer in 2024, that did not repeat in 2025.

Gross margin in the first quarter of 2025 was 75.4% compared to 72.0% in the first quarter of 2024. The increase was largely driven by a favorable shift in product mix.

Operating expenses in the first quarter of 2025 were $4.2 million, down 15% compared to $5.0 million in the first quarter of 2024. The improvement was driven by management of operating costs and the decrease in net revenue.

Income from operations for the first quarter of 2025 was $1.9 million, up 8% compared to $1.8 million in the first quarter of 2024. The increase in operating income was due to a decrease in operating expenses.

Net income in the first quarter of 2025 was $876.3 thousand, up 51% compared to net income of $580.5 thousand in the first quarter of 2024.

EBITDA (a non-GAAP financial measure) in the first quarter of 2025 was $1.98 million, up 7% compared to $1.85 million in the first quarter of 2024. The increase was primarily due to lower SG&A expenses.

Balance Sheet and Cash Flow

As of March 31, 2025, Synergy had approximately $177.9 thousand in cash and cash equivalents, compared to $687.9 thousand in cash and cash equivalents as of December 31, 2024. As of March 31, 2025, Synergy had $31.3 million in total liabilities, compared to $33.0 million in total liabilities as of December 31, 2024, an improvement of $1.7 million.

As of March 31, 2025, Synergy had $2.3 million in inventory, compared to $1.7 million in inventory as of December 31, 2024.

Cash used in operating activities for the three months ended March 31, 2025 was $822.8 thousand compared to cash used in operating activities of $858 thousand for the three months ended March 31, 2024.

EBITDA

Along with this information, to assist financial statement users in an assessment of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and related events, as the Company believes that the non-GAAP information enhances investors' overall understanding of our financial performance, and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP.

The following table reconciles net income to EBITDA (in millions of US dollars):

	3 Months ended March 31
	2025	2024
Net income for the period	$ 0.88	$ 0.58
Adjusted for:
Interest expense, net	1.08	1.11
Amortization of intangible assets	0.03	0.03
Taxes expense (benefit)	(0.01)	0.13
EBITDA	$1.98	$1.85

Conference Call

In conjunction with this announcement, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT on May 15, 2025 with the Company’s Chief Executive Officer, Jack Ross, and the Company’s Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy’s website. To access the call by phone, please register here and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time on the Company’s website.

About Synergy CHC Corp.

Synergy CHC Corp. is a provider of consumer health care and lifestyle products. Synergy's current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain health supplement that has been shown to improve memory, concentration and focus, and Flat Tummy, a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their weight management goals.

Forward Looking Statements

Certain statements contained in this press release constitute "forward-looking statements," including statements regarding expansion and growth initiatives, refinancing of our indebtedness and our free cash flow. These forward-looking statements represent Synergy's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy's registration statement on Form S-1, as amended, many of which are outside of Synergy's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.

Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Synergy’s filings with the SEC. The risk factors and other factors noted in Synergy's filings could cause its actual results to differ materially from those contained in any forward-looking statement.

Investor Relations

Gateway Group
Cody Slach
949.574.3860
SNYR@gateway-grp.com

Synergy CHC Corp. Condensed Consolidated Balance Sheets
	March 31, 2025				December 31, 2024
	(unaudited)
Assets
Current Assets
Cash and cash equivalents	$	177,882			$	687,920
Restricted cash		100,000				100,000
Accounts receivable, net		4,380,518				5,321,037
Other receivables		1,855,000				1,999,637
Loan receivable (related party)		4,375,892				4,375,059
Prepaid expenses (including related party amount of $508,879 and $312,966, respectively)		2,170,263				1,859,563
Inventory, net		2,346,487				1,716,552
Total Current Assets		15,406,042				16,059,768
Intangible assets, net		250,000				283,333
Total Assets	$	15,656,042			$	16,343,101
Liabilities and Stockholders’ Deficit
Current Liabilities:
Accounts payable and accrued liabilities (including related party payable of $217,956 and $88,644, respectively)	$	3,098,590			$	5,191,868
Income taxes payable		77,564				242,977
Contract liabilities		36				24,252
Short term loans payable, net of debt discount		4,754,555				7,725,272
Current portion of long-term notes payable, net of debt discount and debt issuance cost, related party		135,000				4,000,000
Total Current Liabilities		8,065,745				17,184,369
Long-term Liabilities:
Notes payable, net of debt discount, related parties		12,333,053				8,333,053
Notes payable		10,896,610				7,457,022
Total long-term liabilities		23,229,663				15,790,075
Total Liabilities		31,295,408				32,974,444
Commitments and contingencies
Stockholders’ Deficit:
Common stock, $0.00001 par value; 300,000,000 shares authorized; 8,752,178 and 8,721,818, shares issued, respectively; 8,572,105 and 8,541,745 outstanding, respectively		88				87
Additional paid in capital		27,761,307				27,643,660
Accumulated other comprehensive loss		(49,712	)			(47,777	)
Accumulated deficit		(43,223,549	)			(44,099,813	)
Less: Treasury stock (180,073 shares) at cost		(127,500	)			(127,500	)
Total stockholders’ deficit		(15,639,366	)			(16,631,343	)
Total Liabilities and Stockholders’ Deficit	$	15,656,042			$	16,343,101

Synergy CHC Corp. Unaudited Condensed Consolidated Statements of Income and Comprehensive Income
	For the three months ended				For the three months ended
	March 31, 2025				March 31, 2024
Revenue
Product Sales		6,670,534			$	9,411,863
License Revenue		1,500,000				-
Total Revenue		8,170,534				9,411,863
Cost of Sales		2,006,513				2,637,139
Gross Profit		6,164,021				6,774,724
Operating expenses
Selling and marketing		2,876,271				3,584,677
General and administrative		1,306,714				1,348,385
Depreciation and amortization		33,333				33,333
Total operating expenses		4,216,318				4,966,395
Income from operations		1,947,703				1,808,329
Other (income) expenses
Interest income		(13,882	)			(387	)
Interest expense		1,095,369				1,109,980
Remeasurement loss (gain) on translation of foreign subsidiary		1,412				(8,983	)
Total other expenses		1,082,899				1,100,610
Net income before income taxes		864,804				707,719
Income tax benefit (expense)		11,460				(127,189	)
Net income after tax	$	876,264			$	580,530
Net income per share – basic	$	0.10			$	0.08
Net income per share – diluted	$	0.10			$	0.08
Weighted average common shares outstanding
Basic		8,560,636				7,373,745
Diluted		8,577,620				7,373,745
Comprehensive income:
Net income	$	876,264			$	580,530
Foreign currency translation adjustment		(1,935	)			131,637
Comprehensive income	$	874,329			$	712,167

Synergy CHC Corp. Unaudited Condensed Consolidated Statements of Cash Flows
	For the three months ended				For the three months ended
	March 31, 2025				March 31, 2024
Cash Flows from Operating Activities
Net income	$	876,264			$	580,530
Adjustments to reconcile net income to net cash used in operating activities:
Amortization of debt discount and debt issuance cost		406,841				-
Depreciation and amortization		33,333				33,334
Foreign currency transaction loss (gain)		(3,137	)			11,178
Remeasurement gain on translation of foreign subsidiary		(1,412	)			(8,983	)
Non cash implied interest		-				7,199
Changes in operating assets and liabilities:
Accounts receivable		940,519				(318,330	)
Other receivables		144,637				-
Loan receivable, related party		(833	)			25,162
Inventory		(629,935	)			1,016,455
Prepaid expenses		(114,787	)			(202,888	)
Prepaid expense, related party		(195,913	)			(165,687	)
Income taxes payable		(165,413	)			(20,315	)
Contract liabilities		(24,216	)			12,932
Accounts payable and accrued liabilities		(2,218,041	)			(1,808,989	)
Accounts payable, related party		129,312				(19,640	)
Net cash used in operating activities		(822,781	)			(858,042	)
Cash Flows from Investing Activities		-				-
Cash Flows from Financing Activities
Advances from related party		135,000				1,400,000
Repayment of notes payable, related party		-				(84,500	)
Proceeds from notes payable		1,496,250				125,000
Repayment of notes payable		(1,316,572	)			(435,880	)
Net cash provided by financing activities		314,678				1,004,620
Effect of exchange rate on cash, cash equivalents and restricted cash		(1,935	)			131,637
Net decrease in cash, cash equivalents and restricted cash		(510,038	)			278,215
Cash and restricted cash, beginning of year		787,920				732,534
Cash and restricted cash, end of period	$	277,882			$	1,010,749
Supplemental Disclosure of Cash Flow Information:
Cash paid during the period for:
Interest	$	573,529			$	1,102,781
Income taxes	$	-			$	147,728
Supplemental Disclosure of Noncash Investing and Financing Activities:
Accounts payable converted to loan payable upon settlement	$	-			$	3,770,824
Issuance of common stock for loan financing	$	117,648			$	-

FAQ

What was Synergy CHC Corp's (SNYR) earnings per share in Q1 2025?

Synergy CHC Corp reported earnings per share of $0.10 in Q1 2025, representing a 30% increase from $0.08 in Q1 2024.

How much revenue did SNYR generate in Q1 2025?

Synergy CHC Corp generated revenue of $8.2 million in Q1 2025, down 13% from $9.4 million in Q1 2024.

What was Synergy's gross margin in Q1 2025?

Synergy's gross margin improved to 75.4% in Q1 2025, up from 72.0% in Q1 2024, driven by a favorable shift in product mix.

What are Synergy's expansion plans for 2025?

Synergy plans to expand its FOCUSfactor brand and Ready-To-Drink beverages into three new international markets, and has established a subsidiary in Mexico.

How much debt does SNYR have and what are their refinancing plans?

Synergy had $31.3M in total liabilities as of March 31, 2025, and is negotiating debt refinancing to extend maturity to 2029 to improve cash flow and strategic flexibility.